T0	Participants 94 131	for advanced myeloid leukemia and MDS
T1	Participants 847 940	in patients with myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT).
T2	Participants 1318 1322	10%.
T3	Participants 1323 1360	Fifty-one patients have been enrolled
T4	Participants 1400 1405	days.
T5	Participants 1406 1486	There were 32 males and 19 females, with a median age of 45 years (range: 6-59).
T6	Participants 1487 1628	Nine patients had chronic myeloid leukemia (CML) (BC: 2, second AP: 3, and tyrosine-kinase inhibitor refractory first chronic phase [CP]: 4).
T7	Participants 1629 1906	Forty-two patients had AML: 14 were induction failures, 8 in first chemotherapy-refractory relapse, 7 in untreated relapse, 3 in second or subsequent relapse, 4 were in second complete remission (CR), and 3 in second CR without platelet recovery (CRp), 2 were in high-risk CR1.
T8	Participants 1907 1942	Finally, 1 patient was in first CRp
T9	Participants 2153 2163	engrafted.
T10	Participants 2164 2245	Forty-one patients had active leukemia at the time of transplant, and 35 achieved
T11	Participants 2249 2254	(85%)
T12	Participants 2797 2841	safe in high-risk myeloid leukemia patients;